Views: 4 Author: YANG Jing, NI Jia-Liang, GAO Yue-Ying. Publish Time: 2022-04-27 Origin: Protective effects of cordycepin of Cordyceps militaris on ANIT induced cholestatic liver injury. Mycosystema[J], 2021, 40(5): 1160-1169 doi:10.13346/j.mycosystema.200282
This study investigated the ameliorating effect and protective mechanism of cordycepin on α-naphthalene isothiocyanate (ANIT)-induced cholestatic liver injury. First, a model of cholestatic liver injury induced by ANIT was established, and the hepatoprotective effect of cordycepin was evaluated by detecting blood biochemical indexes and HE staining to observe the pathology of liver tissue. Further, the synthesis, decomposition and transport of bile acids were analyzed by Western blot and real-time quantitative PCR technology. and changes in inflammation-related pathways. The results showed that compared with the model group, cordycepin could effectively reduce the level of total bile acids in serum, improve liver function, and significantly reduce liver pathological damage and inflammatory cell infiltration. At the same time, cordycepin activates the bile acid nuclear receptor FXR, up-regulates the expression of bile acid transporters NTCP and BSEP, and relieves the bile acid accumulation in the liver. In addition, cordycepin can also inhibit the expression of IL-6 and IL-1β in liver by regulating the NF-κB signaling pathway. The results suggest that cordycepin has a protective effect on liver injury in ANIT-induced cholestasis model mice, and the mechanism may be related to reducing intrahepatic cholestasis and inhibiting inflammation.
Fig. 1 Effects of cordycepin on the liver morphology (A) and organic index (B) of mice. Compared with control group, *P<0.05, **P<0.01; Compared with model group, #P<0.05, ##P<0.01.
Fig. 2 Effects of cordycepin on blood biochemical in ANIT-cholestatic liver injury mice. Compared with control group, *P<0.05, **P<0.01; Compared with model group, #P<0.05, ##P<0.01.
Fig. 3 Effects of cordycepin on liver histopathological changes in ANIT-cholestatic liver injury mice. A: 200×; B: 400×.
Fig. 4 Effects of cordycepin on bile acid synthesis in ANIT-cholestatic liver injury mice. Compared with control group, *P<0.05, **P<0.01; Compared with model group, #P<0.05, ##P<0.01.
Fig. 5 Effects of cordycepin on bile acid detoxifying enzymes in ANIT-cholestatic liver injury mice. Compared with control group, *P<0.05, **P<0.01; Compared with model group, #P<0.05, ##P<0.01.
Fig. 6 Effects of cordycepin on bile acid transporters in ANIT-cholestatic liver injury mice. Compared with control group, *P<0.05, **P<0.01; Compared with model group, #P<0.05, ##P<0.01.
Fig. 7 Effects of cordycepin on bile acid nuclear receptor FXR in ANIT-cholestatic liver injury mice. Compared with control group, *P<0.05, **P<0.01; Compared with model group, #P<0.05, ##P<0.01.
Fig. 8 Effects of cordycepin on inflammatory response in ANIT-cholestatic liver injury mice. A: The level of IL6 and IL-1β in liver tissue; B: The level of NF-κB p65 in liver tissue. Compared with control group, *P<0.05, **P<0.01; Compared with model group, #P<0.05, ##P<0.01.
